Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Montefiore Medical Center, The Bronx

NYU Winthrop Hospital, Mineola

Winship Cancer Institute: The Emory Clinic, Atlanta

Boca Raton Regional Hospital, Lynn Cancer Institute, Boca Raton

Comprehensive Hematology and Oncology, St. Petersburg

Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie

James Brown Graham Cancer Center:University of Louisville Hospital, Louisville

University of Toledo, Toledo

Allina Health, Virginia Piper Cancer Institute, Minneapolis

The University of Arizona Cancer Center, Tucson

Ochsner Cancer Institute, New Orleans

Mary Crowley Cancer Research Center, Dallas

MD Anderson, Houston

Christus St. Vincent Regional Cancer Center, Santa Fe

Cedars Sinai Medical Center: Samuel Oschin Comprehensive Cancer Center, Los Angeles

William Osler Health System, Brampton

Juravinski Cancer Center, Hamilton

Southlake Regional Health Center, Newmarket

The Ottawa Hospital, Ottawa

Sunnybrook Research Institute, Toronto

Centre hospitalier de l'Université de Montréal (CHUM), Montreal

McGill University Health Center, Montreal

CHU de Québec-Université Laval, Québec